Valerio Therapeutics
ALVIO
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
38
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
Markets appear overly bearish on the company despite the company having attracting growth options.
stocks
Market overreacts to earnings miss from moated ASX retailer
Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,207.30 | 32.70 | -0.35% |
CAC 40 | 7,727.42 | 115.62 | -1.47% |
DAX 40 | 24,196.51 | 76.61 | -0.32% |
Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
FTSE 100 | 9,274.15 | 47.25 | -0.51% |
HKSE | 25,524.92 | 304.99 | -1.18% |
NASDAQ | 21,449.29 | 47.24 | -0.22% |
Nikkei 225 | 42,394.40 | 413.42 | -0.97% |
NZX 50 Index | 12,957.98 | 121.52 | -0.93% |
S&P 500 | 6,439.32 | 27.59 | -0.43% |
S&P/ASX 200 | 8,935.60 | 31.30 | -0.35% |
SSE Composite Index | 3,868.38 | 15.18 | -0.39% |